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Abstract
High serum concentrations of kidney-derived protein uromodulin (Tamm-Horsfall protein or THP) 
have recently been shown to be independently associated with low mortality in both older adults 
and cardiac patients, but the underlying mechanism remains unclear. Here, we show that THP 
inhibits the generation of reactive oxygen species (ROS) both in the kidney and systemically. 
Consistent with this experimental data, the concentration of circulating THP in patients with 
surgery-induced acute kidney injury (AKI) correlated with systemic oxidative damage. THP in the 
serum dropped after AKI, and was associated with an increase in systemic ROS. The increase in 
oxidant injury correlated with post-surgical mortality and need for dialysis. Mechanistically, THP 
inhibited the activation of the transient receptor potential cation channel, subfamily M, member 2 
(TRPM2) channel. Furthermore, inhibition of TRPM2 in vivo in a mouse model, mitigated the 
systemic increase in ROS during AKI and THP deficiency. Our results suggest that THP is a key 
regulator of systemic oxidative stress by suppressing TRPM2 activity and our findings might help 
to explain how circulating THP deficiency is linked with poor outcomes and increased mortality.
One Sentence Summary:
Uromodulin inhibits systemic oxidative stress via TRPM2.
Editor’s Summary
The oxidative hypothesis
Elevated plasma concentration of the kidney-derived protein uromodulin (THP) has been 
associated with better kidney function and decreased mortality in patients with and without kidney 
diseases. However, causal relationship and underlying mechanisms remain unclear. Now, La 
Favers et al. used transgenic mice and showed that THP deletion resulted in systemic oxidative 
damage induced by activation of the transient receptor potential cation channel, subfamily M, 
member 2 (TRPM2) channel. In plasma samples from patients with kidney injury, THP was 
negatively correlated with ROS expression and oxidative damage was associated with increased 
mortality. TRPM2 inhibition in a mouse model of kidney injury reduced the injury-mediated ROS 
increase.
Introduction
Uromodulin (also known as Tamm-Horsfall protein or THP) is a glycoprotein uniquely 
expressed in the kidney by cells of the thick ascending limb (TAL) of the loop of Henle (1–
3). THP is predominantly targeted to the apical surface of cells through a 
glycophosphatidylinositol anchor and secreted in the urine upon cleavage by a serine 
protease recently identified as hepsin (4). However, a smaller, but substantial, amount of 
THP is targeted towards the basolateral domain, making its way into the interstitium and the 
circulation (1, 5, 6). The mechanism by which THP is directed toward the basolateral side of 
the TAL is still unclear. This secretory pathway appears to be favored during stress states, 
such as during recovery from AKI(6, 7). Several studies show that the concentration of 
circulating THP correlates with kidney function and may serve as an inverse biomarker to 
identify early stages of chronic kidney disease (8, 9).
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More recently, THP has emerged as an independent predictor of survival in patients with and 
without kidney disease, whereby elevated concentrations of both urinary and serum THP 
were associated with decreased mortality (10–13). This association, particularly for 
circulating THP, remained valid even after controlling for kidney function (estimated 
glomerular filtration rate or eGFR), suggesting that THP may play an independent 
physiological role, rather than simply acting as a marker of nephron mass and renal activity. 
Although the mechanism underlying this relationship remains unclear, serum THP was 
inversely correlated with inflammatory markers (C-reactive protein) and markers of 
cardiovascular risk (N-terminal pro-B-type natriuretic peptide) (13). It is possible that these 
systemic effects observed with low concentrations of THP are due to activation of 
inflammatory pathways within the kidney that extend systemically. In fact, we previously 
showed that THP deficiency activates the IL-23/IL-17 axis by the kidney, resulting in 
stimulation of granulopoiesis and systemic neutrophilia (14). However, it is also possible 
that THP has direct effects outside the kidney, which could underlie the heretofore 
unexplained systemic outcomes associated with low serum THP.
We previously demonstrated that, within the kidney, interstitial THP is an important 
regulator of the sensitivity of S3 proximal tubules to injury by inhibiting pro-inflammatory 
signaling within these tubular epithelial cells (5, 6, 14–16). We showed that basolaterally 
released THP can bind to the S3 segments, where its presence is essential to inhibit the 
production of cytokines and chemokines such as CXCL2 and IL-23 (5, 6). We believe that 
the crosstalk between THP and proximal tubule segments provides an ideal model for 
elucidating the cellular and molecular mechanisms triggered by THP. By uncovering this 
signaling within kidney cells, we could also identify an underlying mechanism for the 
protective effect of THP systemically.
In this manuscript, we utilized an unbiased combined “omics” methodology to identify the 
molecular signals regulated by THP by taking advantage of our ability to study signaling 
within specific kidney cells/structures, in vivo in mice, using fluorescence-based laser 
microdissection and tissue cytometry. Using this approach, we discovered that RAC1 and c-
JUN N-terminal kinase (JNK) are activated in proximal tubules from THP−/− kidneys. In 
addition, we determined that THP−/− mice have increased oxidative stress not only within 
the kidney, but also systemically in the serum and in the lung, which does not produce THP. 
The translatability of our findings to human disease and the correlation between THP and 
systemic ROS burden was demonstrated in a cohort of patients who developed AKI after 
liver transplant surgery. In this setting, AKI resulted in a drop in serum THP, which was 
associated with elevated post-surgery oxidative damage. High concentrations of oxidative 
damage were associated with systemic outcomes such as 60-day mortality. Lastly, we also 
identified the transient receptor potential cation channel, subfamily M, member 2 (TRPM2) 
as a key target for THP in inhibiting oxidative stress. Findings from this work might 
contribute to the understanding of the modulatory role of THP in the kidney and 
systemically during health and disease.
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Results
Concurrent transcriptomic and proteomic profiling uncovers THP-dependent signaling in 
kidney proximal tubules.
To perform transcriptomic analysis with high precision on isolated S3 (pars recta) proximal 
epithelial tubular cells from THP−/− and THP+/+ mouse kidneys, we performed 
fluorescence-based laser microdissection as described recently (17) (fig. S1A), followed by 
gene microarrays on the extracted RNA (Fig. 1A). Analysis of the data uncovered 956 genes 
that were up-regulated and 848 genes that were downregulated in S3 cells from THP−/− vs. 
THP+/+ kidneys, respectively. Bioinformatic analysis using Ingenuity (Qiagen) identified 
several canonical pathways predicted to be differentially regulated in THP−/− vs. THP+/+ S3 
proximal epithelial cells, shown in Fig. 1B (p <0.05). Among these identified pathways, c-
JUN-N-terminal kinase (JNK) signaling had the highest z-score for activation (z-score 3.3, 
fig. 1B, fig. S1B, C). Disease annotation analysis showed that the differential gene 
expression pattern caused by THP loss in S3 cells was associated with patterns observed in 
renal damage and injury pathways (fig. S1D).
Next, we adopted an orthogonal approach to discover the protein expression changes elicited 
by treatment of proximal tubular epithelial cells with THP using label-free quantitative mass 
spectrometry-based proteomics (LFQMS) (18, 19). We incubated HK-2 human proximal 
tubular cells with purified human THP or vehicle, after which we measured the changes in 
expression of 1881 proteins identified by LFQMS (Fig. 1C). At 6 hours, THP caused 
changes in the expression of 406 proteins. Using bioinformatic analysis on the differentially 
expressed proteins, most of the top canonical pathways affected by THP treatment were 
linked to the inhibition of RAC1 signaling (Fig. 1D). Since RAC1 activation occurs at the 
plasma membrane and can lead to downstream activation of JNK signaling (20), RAC1 itself 
could link THP to JNK activation (fig. S2). Therefore, together with the transcriptomics 
data, our findings suggest that THP might inhibit the RAC1/JNK signaling pathway in 
proximal tubules.
THP deficiency activates the RAC1/JNK/c-JUN signaling pathway in proximal epithelial 
cells.
To validate and further link the transcriptomic and proteomic data, we next surveyed RAC1 
activation in kidneys from THP−/− and THP+/+ mice. Confocal microscopy showed that 
RAC1 shifted from a cytoplasmic localization to the basolateral domain of S3 tubular 
segments in the absence of THP in the outer stripe, but not in the cortical S1/S2 proximal 
tubules (Fig. 1E, fig. S3). Because RAC1 is activated at the basolateral domain, its shift is a 
reliable surrogate for activation (21). Immunoprecipitation of activated RAC1 was 
performed on kidney lysates. RAC1 activation was significantly increased in the setting of 
THP deficiency (Fig. 1F, p<0.05). Phosphorylated (activated) JNK in nuclear extracts from 
total kidney lysates was significantly increased (p<0.05) in THP−/− kidneys compared to 
THP+/+ kidneys (Fig. 1G). Consistent with the changes in JNK activity observed in the THP
−/−
 kidney, we also observed that THP inhibits JNK activation in HK-2 proximal tubular 
cells (Fig. 1H).
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Furthermore, active JNK leads to phosphorylation of c-JUN (p-c-JUN), which is a member 
of the AP-1 transcription factor and has been implicated in the transcription of a myriad of 
inflammatory cytokines, including IL-23 (22). We utilized 3D quantitative imaging and 
analysis to quantitate the number of p-c-JUN+ cells in THP−/− and THP+/+ in sections from 
the outer medulla and cortex of the kidney (Fig. 2A, B) using volumetric tissue exploration 
and analysis software (VTEA, (23)). Since these kidney sections originated from naïve mice, 
expression of p-c-JUN in THP+/+ was negligible (0.03 ± 0.01% in the outer medulla, 0.08 ± 
0.08 % in the cortex, Fig. 2B). In THP−/− outer medulla and cortex sections, p-c-JUN 
expression was significantly increased compared to THP+/+ (0.98 ± 0.31% and 1.0 ± 0.74%, 
respectively, p<0.05, Fig. 2B). A three dimensional rendering overlaying phospho-c-JUN 
staining of nuclei with phospho-c-JUN positive cells gated by VTEA demonstrated the 
accuracy of the gating approach and confirmed that c-JUN activation was limited to 
proximal tubules (Fig. 2C). Cumulatively, these data show increased activation of 
RAC1/JNK/c-JUN in THP−/− kidneys. For RAC1, this appears to be predominantly evident 
in S3 proximal tubules, whereas increased c-JUN activation occurs in most proximal tubules 
within the kidney. Taken together with the transcriptomic and proteomic analyses shown so 
far, we concluded that THP deficiency stimulates the activation of RAC1/JNK/c-JUN in the 
kidney in mice.
Proteomic analysis of S3 proximal cells reveals dysregulation of the free radical 
scavenging network in THP−/− mice.
To further characterize the changes elicited in S3 proximal epithelial tubular segments in the 
setting of THP deficiency, we performed targeted proteomic analysis on S3 proximal 
epithelial cells in mice. This was achieved by isolating S3 segments by laser microdissection 
from THP+/+ and THP−/− kidneys, followed by protein extraction and two-dimensional 
differential gel electrophoresis (2D-DIGE), as described in a recent publication (fig. S4A–C) 
(17). Differentially expressed proteins were identified by mass spectrometry (fig. S4D). 
Bioinformatics analysis of the differentially expressed proteins identified the free radical 
scavenging network as the top network of proteins that was differentially regulated in THP
−/−mice (fig. S4E). This analysis predicted increased generation of reactive oxygen species 
(ROS) in S3 segments from THP−/− compared to THP+/+ mice. (fig. S4F).
The predicted redox imbalance within the THP−/− S3 tubules was consistent with the 
observed activation of the RAC1/JNK/c-JUN signaling pathway in these mice. This 
connection between ROS and RAC1/JNK signaling was highlighted in the combined 
signaling/oxidative stress bioinformatics model (fig. S5).
THP deficiency leads to increased oxidative stress and damage within the kidney.
Given the predicted redox imbalance of S3 segments within THP−/− kidneys, we performed 
live imaging of kidneys from mice injected with a redox sensitive dye, H2DCFDA,. We 
found that THP−/− mice have a higher burden of oxidative stress throughout the kidney 
cortex (Fig. 3A, p<0.05). We extended these findings to the kidney medulla using another 
redox sensitive dye (CellROX Deep Red) which helped to localize a ROS signal to the S3 
segments (fig. S6A, B, p<0.05). To further quantitate the differences in oxidative stress 
found in THP−/− mice, we measured hydrogen peroxide (H2O2) directly using a colorimetric 
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assay and found that its concentration was significantly increased in total kidney lysates 
from THP−/− kidneys compared to THP+/+ (Fig. 3B, p<0.05). Taken together, these results 
suggest that kidneys from THP−/− mice have an increased ROS burden throughout the 
kidney, particularly within the S3 tubules.
To determine what types of damage might be occurring as a result of the increased oxidative 
stress burden within the THP−/− kidneys, we first quantitated the oxidized forms of the 
major classes of phospholipids in kidney lysates using targeted lipidomics. A heat map 
showing the relative quantity of oxidized phospholipids in THP+/+ and THP−/− is shown in 
Fig. 3C. Specifically, we found that THP−/− kidneys have increased amounts of oxidized 
phosphatidylcholine (Fisher’s exact test, p<0.0001) and phophatidylethanolamine (Fisher’s 
exact test, p<0.0001) lipids as compared to THP+/+ kidneys (Fig. 3C, Data File S3). Since 
oxidative stress is known to cause organelle dysfunction, we investigated mitochondrial 
morphology in S3 proximal tubules using toluidine blue staining and electron microscopy 
studies. We observed increased mitochondrial swelling and deformation in S3 cells of THP
−/−
 compared to THP+/+ mouse kidneys (fig. S7A–C, two-way ANOVA, p<0.0001). 
Collectively, these data further establish that THP deficiency increases oxidative stress in the 
kidney, particularly in proximal tubular segments. Given our previous data that THP−/− 
kidneys have increased expression of IL-23 within the S3 tubules, we hypothesized that 
increased oxidative stress within the S3 tubular cells leads to increased IL-23 expression. In 
fact, we found that treatment of HK-2 cells with H2O2 leads to an increase in IL-23 mRNA 
expression (fig. S8), providing a potential link between these two observations.
THP Deficiency Leads to Systemic Oxidative Damage.
Given the role that THP deficiency plays in increasing oxidative stress and damage within 
the kidney, along with our previous data showing that the loss of THP can lead to systemic 
effects on inflammation (24) and neutrophil homeostasis (14), we hypothesized that the 
basolateral release of THP into the interstitium and circulation could mitigate the buildup of 
oxidative damage systemically. We measured oxidative DNA damage in the kidneys, serum 
and lungs in THP+/+ and THP−/− mice using an assay for 8-hydroxy-2’-
deoxyguanosine(8OHdG) (25), which provides a robust method to quantify oxidative 
damage that could be used in both tissue lysates and serum. As expected, THP−/− mice had 
higher DNA damage in the kidneys (Fig. 3D, p<0.05), but we also observed higher 
concentrations in the serum (Fig. 3E, p<0.001) and the lungs (Fig. 3F, p<0.05). From this 
data, we conclude that the loss of THP leads to increased oxidative damage not only in the 
kidneys, but also in the serum and in the lung, an organ that is not known to produce THP. 
These findings suggest that circulating THP, through an effect distant from the kidney, might 
mitigate systemic oxidative damage.
To test the relevance of these findings in disease, we subjected THP+/+ mice to AKI using 
the ischemia reperfusion injury (IRI) model. We found that serum THP decreased twenty-
four hours post-surgery (Fig. 4A), while oxidative DNA damage and kidney function/injury 
markers increased (Fig. 4B, C). Therefore, these results extend the findings from the THP−/
− mice to a disease model in THP+/+ mice, where a decrease in systemic THP was observed 
in early AKI, concomitant with increased systemic oxidative stress.
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Plasma THP concentrations drop during human AKI, and are associated with increased 
systemic oxidative damage and outcomes
To test the translatability and relevance of these findings to human disease and validate the 
relationship of THP with oxidative stress, we measured changes in plasma THP and 
oxidative stress among 41 patients with liver diseases before and 18 hours after liver 
transplantation. Demographics and clinical variables for this cohort are shown in Tables 1 
and S1. Baseline measurements were not different compared to a small number of control 
subjects who did not undergo liver transplantation (Table S1), supporting that the liver 
disease burden in this cohort did not affect the baseline measurements. In patients who did 
not develop post-surgery AKI, pre-surgery baseline eGFR was higher (Table S1), consistent 
with previous reports that pre-surgical kidney function is an important risk factor of post-
surgery AKI (26, 27).
In 34 patients who developed AKI based on the Kidney Disease Improving Global 
Outcomes (KDIGO) serum creatinine criterion (28), THP concentrations were inversely 
correlated with systemic DNA damage (Fig. 5A, R2= 0.06, p<0.05), which is consistent with 
the mouse data above. When compared to pre-surgery concentrations, plasma THP 
decreased significantly at 18 hours following surgery in patients with AKI (Fig. 5B, Table 1, 
291 ±258 ng/ml vs. 102 ± 93.6 ng/ml, p<0.001). These findings confirm, in humans, that 
AKI results in a state of acute systemic THP deficiency. This decrease in THP was 
concomitant with a significant increase in oxidative DNA damage (Fig. 5C, Table 1, 11.8 ± 
8.14 ng/ml vs. 16.3 ± 11.8, p<0.05). Pre-surgery concentrations of THP in patients with AKI 
were inversely correlated with post-surgery DNA damage (Fig. 5D, R2 = 0.23, p<0.05), 
demonstrating that higher baseline THP correlated with lower oxidative damage incurred 
post-surgery. In patients who did not develop post-surgery AKI, there was no statistical 
difference between pre and post-surgery THP, although concentrations were lower, on 
average, post-surgery (fig. S9).
Although this human study was not designed, nor powered, to detect a relationship between 
THP and/or oxidative stress concentrations with other endpoints such as mortality or need 
for dialysis, we did find that the post-surgery oxidative DNA damage plasma concentrations 
were increased in non-survivors (Fig. 6B, 14.0 ± 9.94 ng/ml in survivors vs. 23.6 ± 14.7 
ng/ml in non-survivors, p<0.05). Pre-surgery concentrations of plasma oxidative DNA 
damage did not differ between survivors and non-survivors (Fig. 6A) suggesting that 
elevated oxidative damage in the plasma as early as 18 hours post-surgery may be a 
predictor of mortality. However, plasma THP both before (Fig. 6C) and after (Fig. 6D) 
development of AKI was not different in non-survivors compared to survivors. Oxidative 
DNA damage pre and post-surgery was higher in patients who subsequently required 
dialysis (p<0.05, Fig. 6E, F). Together with the animal data presented above, these results 
suggest that high concentrations of circulating THP may be protective from increased 
oxidative stress.
THP inhibits systemic oxidative stress through TRPM2.
Having established the signaling pathways activated during THP deficiency and the resultant 
oxidative damage, we set out to determine the molecular target linking THP with increased 
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oxidative stress and activated RAC1/JNK signaling. We hypothesized that THP could targets 
a RAC1 modulator. One of the candidate molecules is the transient receptor potential cation 
channel, subfamily M, member 2 (TRPM2). TRPM2 is a non-voltage activated, Ca2+-
permeable, non-selective cation channel that plays an important role in ROS-coupled 
diseases (41, 42) Therefore, we hypothesized that THP inhibits TRPM2 and the downstream 
RAC1/oxidative stress/JNK signaling pathway. THP was recently shown to regulate the 
activity of a related channel, TRPM6 (29).We first investigated whether THP can directly 
alter the function of TRPM2 using a HEK 293 recombinant cell line expressing an inducible 
copy of TRPM2 in which channel specific activation can be monitored by measuring the 
kinetics of calcium influx after stimulation with H2O2, which increases the open state of the 
channel (30). Using this approach, we showed that THP inhibited TRPM2 activity (Fig. 7A), 
leading to complete inhibition of TRPM2-mediated calcium influx. This effect was specific 
(Fig. 7B) to THP, since similar inhibition was not shown with human serum albumin (HSA), 
and dose dependent (Fig. 7C). The potency of this inhibition was also equivalent to N-(p-
amylcinnamoyl) anthranilic acid (ACA), a known TRP channel blocker (31) (Fig. 7D). 
Therefore, our data demonstrate that THP specifically inhibits the activation of TRPM2. 
Consistent with this finding, inhibition of TRPM2 in HK-2 cells with ACA blocked JNK 
activation, as was previously demonstrated with THP (fig. S4, Fig. 8), suggesting that the 
inhibitory effect of THP on JNK activation is at least partially dependent on TRPM2.
TRPM2 is expressed at high concentrations in the brain and immune system, and to a 
varying degree in other organs such as heart, spleen, liver, pancreas and kidney (32). Due to 
its broad expression profile in immune cells and the demonstrated inhibition by THP in 
vitro, we hypothesized that TRPM2 mediates the systemic oxidative damage observed in 
THP−/− mice. To test this hypothesis, we treated THP−/− mice with the TRPM2 inhibitor 2-
Aminoethoxydiphenyl borate (2-APB), previously used for in vivo studies, (33) and found 
that 2-APB significantly lowered systemic oxidative DNA damage in these mice (Fig. 7E, 
p<0.05). To extend these findings to AKI, where TRPM2 was shown to promote ischemia 
reperfusion injury (IRI) (34), we subjected THP+/+ and THP−/− mice to IRI following 
TRPM2 inhibition with 2-APB and measured oxidative damage in the serum 6 hours later. 
The vehicle-treated THP−/− mice showed increased oxidative damage as compared to 
vehicle-treated THP+/+ mice, mirroring the results in uninjured animals (Fig. 7F, p<0.05). 
Furthermore, pre-treatment of both the THP+/+ and THP−/− mice with 2-APB significantly 
reduced oxidative damage post-IRI (Fig. 7F, p<0.05 and p<0.01, respectively). The 
difference in oxidative damage seen between the THP+/+ and THP−/− mice was lost upon 
treatment with 2-APB, implying that TRPM2 is a main target for the inhibitory effect of 
THP on systemic oxidative stress.
Discussion
In this study, using a combination of experimental approaches and a small human cohort, we 
show a role for THP in maintaining redox balance not just in the kidney, but also 
systemically. This protective effect of THP against systemic oxidative stress occurs by 
inhibiting TRPM2 channel activation. Since TRMP2 is expressed in many organs throughout 
the body, particularly in the immune system (32), uncovering the THP-TRPM2 link provides 
a potential mechanism by which the kidney impacts other organs following the release of 
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THP into the circulation. It is important to note that non-specific targeting of TRPM2 itself 
is likely to be risky, because of its pleotropic constitutive expression and tissue specific 
effects (35). However, targeted interventions that modulate the concentration of systemic 
THP may hold a future therapeutic potential, especially in view of recent experimental data 
that support such interventions (36).
We found that there is increased oxidative stress in proximal tubules, both within the cortex 
(predominantly S1/S2 proximal tubules) and the outer medulla (predominantly S3 proximal 
tubules) in kidneys from THP−/− mice. Oxidative stress results from an imbalance between 
generation of ROS such as superoxide and hydrogen peroxide, and the reductive buffer 
system that quenches the excess of these toxic molecules (37). Within the cells, ROS at low 
levels are essential byproducts of oxidative phosphorylation and needed for signal 
transduction (37–40). However, excess ROS will damage the cell through multiple 
pathways, such as direct damage to organelles, macromolecules, and impairment of normal 
functioning systems, leading eventually to cell death. Interestingly, ROS can directly 
stimulate inflammatory signaling, such as NFkB and AP-1-dependent pathways, leading to 
the production of a myriad of pro-inflammatory cytokines (37, 38). Therefore, by inhibiting 
oxidative stress, THP can potentially regulate both cell fate of S3 segments and the 
production of inflammatory mediators, such as IL-23.
We also found that the RAC1/JNK/c-JUN pathway is activated in these tubules. Oxidative 
stress stimulates RAC1/JNK/c-JUN signaling (41) and links the proteomics analysis of S3 
tubules to the transcriptomic analysis of S3 tubules. Many of the proteins dysregulated in the 
S3 tubules of THP−/− mice, including ALBU, ALDH3, GPX3, and SODC, are also linked to 
RAC1/JNK signaling, either as upstream regulators or targets (42–53). Our data suggested 
that the burden of oxidative stress may be accentuated in S3 segments, which is also 
supported by the differential shift of RAC1 to the basolateral membrane in outer medulla 
cells. This is not surprising, given the fact that the absence of THP may be more impactful in 
the outer medulla than the cortex, due to a relatively higher frequency of TALs in this 
region, which are likely releasing higher amounts of THP into the interstitium surrounding 
S3 tubules (6). JNK activation, as measured by phosphorylation of c-JUN, is present in both 
the cortex and the medulla, which may reflect the generalized presence of oxidative stress 
and the high sensitivity of the 3D imaging assay used.
Circulating THP has been shown to correlate with kidney function (8, 9), is inversely 
associated with CKD and predicts the risk of developing CKD (54). Of note, risk variants in 
the UMOD promoter region may be independent modifiers of CKD risk and further studies 
are needed to investigate their interaction (55), especially how they may be associated with 
the concentrations of circulating THP. Our study does not specifically address how 
circulating THP is linked to the risk of CKD. It is possible that the decrease in THP 
production and systemic release observed in CKD (54) can lead to increased ROS within the 
kidney, thereby predisposing it to ongoing tubular injury and fibrosis (56). This hypothesis 
will need to be tested in models of chronic kidney disease.
TRPM2 is a multifunctional non-selective calcium ion channel. It is expressed in high levels 
in the brain, but also in other organs such as heart, spleen, liver, bone marrow, pancreas and 
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kidney (32). Within organs, its expression is uneven with specific cells exhibiting a high 
level of expression (32). In the kidney specifically, the link between TRPM2, RAC1-
dependent signaling and oxidative stress in epithelial cells has been recently demonstrated in 
the context of AKI (34). In our study, we extended these findings by showing that THP 
could be an important regulator of TRPM2, RAC1 and oxidative stress. We also showed that 
THP deficiency, whether genetic or due to AKI, was associated with elevated systemic 
oxidative damage. The increased systemic ROS burden was mitigated by treatment with a 
TRPM2 inhibitor, suggesting that it is at least partially TRPM2 dependent. The relationship 
between ROS and TRPM2 is complex because TRPM2 is both activated by ROS and can 
also amplify downstream oxidant damage (57). Our work may help clarify this relationship 
by identifying THP as an upstream mediator of TRPM2 and ROS.
Findings from this study provide a mechanism that could help to explain how serum THP is 
linked with systemic outcomes such as all-cause mortality and may have a high clinical 
impact. When interpreted with other clinical data linking reduced serum THP to mortality 
(11, 13), our current findings suggest that regulation of systemic oxidative stress is a 
mechanism that helps explain this link. The increased susceptibility to oxidative stress has 
particular implications in diseases leading to acute THP deficiency, such as AKI, which is 
supported by our data exploring the relationship between THP and oxidative damage in 
human AKI. Our study also provides a rationale to explore the sensitivity of serum THP as a 
biomarker for early AKI in large studies, especially with a trend in decreased THP even 
observed in patients who did not develop AKI by standard clinical criteria. Finally, our 
findings also raise the possibility of using THP and oxidative stress measurements to 
prognosticate and guide overall clinical management post-AKI. These prospects will require 
validation in a large prospective study before they can be utilized in the clinic.
A major strength of our experimental design was the use of a multi-disciplinary approach, 
combining complementary “omics” and imaging techniques that converged on a specific 
finding, which we were able to translate from experimental models to patients. Though this 
strategy could help to overcome experimental limitations, it is important to note these 
limitations to facilitate interpretation. Although the exact sub-segmental origin (S1–S2 or 
S3) of the HK-2 cells utilized for the proteomic studies of THP-treated cells is not well 
established, there is currently no suitable alternative, because there are no available S3 
specific pure human cells (58). In addition, HK-2 cells are among the most characterized and 
commonly used human tubular epithelial cells, which can facilitate the reproducibility of 
this work. The use of these human cells also allows the extension of the findings to human 
pathology. For the THP treatment cell studies, the monomeric THP used to mimic 
basolaterally released THP is cleaved differently than serum THP, which is a potential 
limitation of this work (36). Additionally, the interpretation of these findings needs to be 
balanced by the fact that the dose of THP used in the HK-2 cell experiments is likely in the 
pharmacological range, compared to circulating concentrations. However, in the TRPM2 
inhibition experiments even physiological concentrations inhibit TRPM2-mediated calcium 
influx. For the human studies, the statistical power to establish relationships between THP, 
oxidative stress and clinical variables is limited by the sample size, which also restricted our 
ability to make comparisons between patients who developed more or less severe kidney 
injury. Finally, although the use of a transgenic cell line for the TRPM2 studies allowed us to 
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show specific inhibition of the TRPM2 channel, we are unable to determine which TRPM2-
expressing cells are the primary targets of THP inhibition in vivo, which will require 
additional studies to establish.
In conclusion, our study suggests that circulating THP is an important regulator of renal and 
systemic oxidative stress. Findings from this work could advance our understanding of the 
modulatory role of THP in the kidney and systemically during health and disease.
Materials and Methods
Study Design
In this study, we studied the S3 proximal tubules in THP−/− mice to generate, and 
subsequently test, hypotheses about THP’s function. We utilized laser microdissection to 
isolate S3 proximal tubules from THP+/+ and THP−/− mice and performed transcriptomic 
and proteomic studies on the samples. In parallel, we treated a proximal tubular cell line 
with THP prior to proteomic analysis. Additional experiments were performed to validate, 
explore and expand on these results, as described in the following methods sections. Sample 
sizes were established for different analyses as follows. For in vitro experiments, all 
experiments were performed with three technical replicates and were repeated a minimum of 
1–2 additional times to ensure reproducibility. For animal experiments in uninjured animals, 
a pilot experiment with 3–5 animals per group was first conducted to measure effect size and 
conduct power calculations to scale up the experiment accordingly. For animal experiments 
using the IRI model of AKI, experiments were conducted with 8–10 mice per group, based 
on the number of mice required for significance in uninjured animals along with feasibility 
considerations. The subjects were not randomly assigned to experimental groups due to 
animal housing considerations. The study was not blinded. All data acquired is presented in 
the main figures and supplementary data.. These criteria were established prospectively. 
Statistical outliers were defined using the Tukey’s fences methods, unless otherwise 
described in the specific methods sections.
Mice
Animal experiments and protocols were approved by the Indianapolis VA Animal Care and 
Use Committee. Age matched 8–12 week-old Tamm-Horsfall protein (THP) knockout male 
mice (129/SvEv THP−/−) and wild type background strain were used as described previously 
(6, 7). For 2-APB dosing experiments, mice were dosed as described previously (34), with 
either 16 mg/kg 2-APB in 90% saline/10% DMSO or vehicle control (90% saline/10% 
DMSO), once daily for three days before collecting organ and serum samples. Ischemia 
reperfusion injury was performed as described previously (16), following dosing with 2-
APB or vehicle control for three days as indicated for each experiment. The final dose of 2-
APB or vehicle control was given prior to the beginning of ischemia reperfusion injury 
surgery. Mice were allowed to recover for six hours before collecting organ and serum 
samples.
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Immuno-fluorescence confocal microscopy and 3D tissue cytometry
Immuno-fluorescence staining for RAC1 (Millipore, Cat #05–389), DAPI (Sigma Aldrich, 
Cat #D9542), p-c-JUNC-JUN (Cell Signaling Technology, Cat #3270S) and FITC-
phalloidin (Molecular Probes, Cat. #D1306 and #F432) was performed on 50 μm vibratome 
sections of kidneys fixed with 4% para-formaldehyde as described previously (6). Briefly, 
immunostaining was done at room temperature, overnight, with primary antibody in PBS + 
2% BSA + 0.1 % Triton X-100 and secondary antibody + FITC-phalloidin + DAPI in the 
same buffer. After mounting on glass slides, stained sections were viewed under Olympus 
Fluoview laser-scanning confocal microscope. Images were collected under X20 and X60 
magnification. Quantitation of the cellular distribution of RAC1 fluorescence in proximal 
tubules (identified by Oregon 488-green phalloidin staining of the brush borders) was 
performed on high power fields (2 fields per section, 1 section per mouse, 5 mice per each 
experimental group), using ImageJ. Basolateral membrane associated RAC1 average 
intensity was measured along the basolateral border (outlined by F-actin staining) in a 4 
pixel (1.56 μm) spanning region of interest using a brush tool (Fig. S3). Cellular RAC1 
average intensity for each corresponding tubule was measured in the remaining area. The 
ratio of membrane associated RAC1: cellular RAC1 was calculated for each tubule. 3D 
tissue cytometry was performed with Volumetric Tissues Exploration and Analysis (v0.5.2) 
(23). Briefly, cells were segmented by their nuclei. Identifying cell-types or cell 
characteristics was accomplished by measuring the intensity of markers either within the 
putative nuclei or a small surrounding volume generated with a morphological dilation. 
These measurements are collated and plotted on an interactive scatter plot, which can be 
interrogated with gating approaches. Here, p-c-JUN intensity was assessed in the nuclei of 
segmented cells and positive cells were gated and counted.
Electron Microscopy
Upon harvesting, kidneys were perfused-fixed with 3% glutaraldehyde buffered with 0.15M 
sodium cacodylate, and subsequently embedded in Poly Bed 812 embedding mixture resin. 
For light microscopy, 0.5μm-thick sections were cut using an ultramicrotome, and stained 
with toluidine blue. For transmission electron microscopy, 70–90 nm sections were cut, 
collected on 200 mesh copper grids, viewed and photographed on a Tecnai electron 
microscope. We quantified mitochondrial swelling by measuring the maximum length of the 
short axis for all mitochondria within 5 cells from the representative images shown for THP
+/+
 and THP−/− mice.
Laser Micro-dissection
Kidneys were extracted after euthanasia. Sections from each kidney were snap frozen in 
OCT compound (Tissue-Tek, Cat. #4583) on dry ice and kept at −80° C until use. They were 
subsequently cut using a cryotome at 10 μm sections and mounted on Leica PPS membrane 
slides (Leica, Cat. #11505268). The protocol for staining S3 proximal tubules, described 
previously in detail (17), identifies these tubules by the intense brush border stain in the 
outer medulla. Following rapid dehydration/re-hydration steps the samples were stained with 
FITC-phalloidin (1:20) + DAPI (Molecular Probes, 1:300), washed with PBS and the 
membranes were allowed to air dry. Following staining, sections were immediately taken to 
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a Leica LMD6000 Laser micro-dissection microscope. Dissection was performed at 40x 
magnification under fluorescence. There were 200–250 segments dissected in each 90-
minute session (average dissected area varies on type of tubules, for S3 segments this ranges 
from 350,000 – 500,000 μm2). RNA extraction was performed using Arcturus PicoPure 
RNA isolation kit (Applied Biosystems).
Micro-arrays
Total RNA was analyzed using the Agilent Bioanalyzer (Agilent Technologies) to assess the 
quality. Samples were processed in two batches with THP−/− and THP+/+ samples in each 
batch. Two ng of total RNA for each sample was labeled using the standard protocol for the 
Affymetrix WT Pico kit (Affymetrix). Individual labeled samples were hybridized to the 
Mouse Gene 2.0 ST GeneChipsfor 17 hours then washed, stained and scanned with the 
standard protocol using Affymetrix GeneChip Command Console Software (AGCC) to 
generate data (CEL files). Arrays were visually scanned for abnormalities or defects; none 
were found.
CEL files were imported into Partek Genomics Suite 6.6 (Partek, Inc.) for analysis. RMA 
(Robust multichip average (59)) expression values were generated for all probe sets using 
the RMA background correction, Quantile normalization and summarization by Median 
Polish. Summarized signals for each probe set were log2 transformed. These log 
transformed signals were used for Principal Components Analysis, hierarchical clustering 
and signal histograms to determine if there were any outlier arrays. No outliers were found. 
Data were analyzed using a 2-way ANOVA with factors for genotype (THP−/−/THP+/+) and 
labeling batch. The contrast for THP−/−/ vs. THP+/+ was performed, and fold changes were 
calculated using the untransformed RMA signals. Probe sets with log2 expression values < 
3.0 were below background. Probe sets (transcripts) with average expression values < 3.0 for 
all experimental groups (60) and Affymetrix control probe sets were removed.
Hierarchical clustering of differentially expressed genes was done in Partek, using Euclidean 
distance for arrays and Pearson’s dissimilarity for genes with average linkage.
Protein extraction, 2-dimensional differential gel electrophoresis (2D-DIGE) and Mass 
spectrometry
This experiment has been described in detail in an initial publication (17). Briefly, 2D-DIGE 
was performed on S3 segments isolated from wild type (THP+/+) and Tamm-Horsfall Protein 
knockout (THP−/−) mice using IF-LMD (performed by Applied Biomics). In brief, an initial 
analytical gel was done by using 50 μg of protein extract from each S3 sample (THP−/− and 
THP+/+). Each sample was labeled with Cy2 or Cy3, mixed and separated on a 2D gel. In-
gel data analyses for protein spots and comparison of the integrated volumetric ratios were 
done using the DeCyder software. Spots chosen by the DeCyder software were identified 
using mass spectrometry (MALDI/TOF then MALDI/TOF/TOF) on the basis of peptide 
fingerprint mass mapping and peptide fragmentation mapping. The MASCOT search engine 
was used to identify proteins from primary sequence databases.
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Measurement of oxidative stress in vivo
A hydrogen peroxide assay (Abcam, Cat. #102500) was used to measure the concentration 
of H2O2 in kidney lysates from THP−/− and THP+/+ mice, following the manufacturer’s 
instructions. Concentrations were normalized to the amount of protein present in each 
sample.
Using intravital microscopy, oxidative stress was measured in the live animals with 
H2DCFDA (Life Technologies). H2DCFDA was administered intravenously as a 7 mg/kg 
bolus from a stock dissolved in ethanol and rediluted in PBS. Images were collected before 
injection and 20 minutes after H2DCFDA administration, as we described previously (61). 
Fluorescence intensity was measured using ImageJ in 3–4 fields (20X objective) per animal; 
the values for each animal were expressed as a fold change over background intensity 
(image taken just prior to injection).
To localize the site of oxidative stress, we used an in vivo redox dye CellROX Deep Red 
(Life Technologies, Cat. #C10422). THP+/+ and THP−/− mice were injected with Hoechst 
33342 (50 μg/mouse, Molecular Probes, Cat. #H3570) and CellROX (50 μl/mouse of 2.5 
mM solution) intraperitoneally, and mice were euthanized 2 hours later and immediately 
sectioned for imaging using confocal microscopy. Another set of kidneys were fixed with 
4% paraformaldehyde and imaged following co-staining with FITC-phalloidin. Fluorescence 
intensity was measured using ImageJ in 2–4 fields (20X objective) per animal and the values 
for each animal were expressed as a fold change over the negative control (THP+/+ mouse 
injected with Hoechst 33342 only).
Tamm-Horsfall protein purification
Tamm-Horsfall protein was purified from normal human urine according to the method 
described by Tamm and Horsfall (62, 63). THP was subsequently treated with urea, and 
resolved using gel filtration to recover a non-aggregated form in the range of 60–120 
kiloDaltons (kDa), as we described recently (36). The purified THP was kept in a 5% 
Dextrose water solution. In all in vitro experiments, the concentration of endotoxin was < 
0.02 EU/ml, measured using Limulus Amebocyte Lysate (LAL) assay.
HK-2 cells
HK-2 cells were obtained from ATCC (Cat. # CRL-2190) and grown in KSFM medium 
(Gibco Cat. #1074–019) according to manufacturer’s instructions. THP at a concentration of 
1 μg/ml or vehicle (5% Dextrose) were added in the experimental wells. For RNA studies, 
cells were incubated for 1 and 4 hours, and RNA was extracted as described below. For 
proteomic studies, cells were harvested at 6 hours and processed for protein extraction as 
previously described (36). For the indicated experiments, hydrogen peroxide (1mM) was 
added to HK-2 cells for 1 hour, and cells were allowed to recover in media for 1 hour before 
RNA extraction. All experiments were performed in triplicate. For the JNK activation 
experiments, cells were incubated with THP (1μg/ml), H2O2 (1 mM) or ACA (25 μM) as 
indicated for 1 hour. In pre-treatment experiments, cells were incubated with THP or ACA 
alone as indicated prior to adding H2O2 (1mM) for an additional half an hour. All cells were 
allowed to recover in media for 1 hour before processing for protein extraction.
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Real time PCR
RNA extraction from whole kidneys and from HK-2 cells was done using TriReagent 
(Ambion, Cat. #AM9738) according to manufacturer’s protocol, and reverse transcribed as 
previously described (6). Real-time PCR was performed in an Applied Biosystems (AB) 
ViiA 7 system using TaqMan Gene Expression Assays also from AB. The following primers 
were used for human cell studies: IL-23: Hs 00900828_g1; 18s rRNA: Hs 99999901_s1. 
Cycling parameters were: 50°C for 2 min, then 95°C for 10 min followed by 40 cycles of 
95°C for 15 sec and 60°C for 1 min. Expression values were normalized to endogenous 
controls and reported as fold change compared to control using the delta-delta CT method, 
according to the manufacturer’s instructions.
RAC1 activation assay
RAC1 activation assay was performed using a kit from Millipore (Cat. #17–283). Band 
densitometry was done using ImageJ (NIH).
Label-free quantitative mass spectrometry (LFQMS) proteomic studies
Triplicate protein extracts from HK-2 cells, treated with THP or vehicle, were analyzed 
using LFQMS as previously described (18, 19). In brief, HK-2 proteins were digested with 
trypsin and peptides analyzed using a Thermo-Finnigan linear ion-trap (LTQ) mass 
spectrometer coupled with a Surveyor autosampler and MS HPLC system (Thermo-
Finnigan). The data were collected in the “Data dependent MS/MS” mode with the ESI 
interface and searched against the International Protein Index (IPI) HUMAN database using 
SEQUEST (v. 28 rev. 12) algorithms in Bioworks (v. 3.3). The searched peptides and 
proteins were validated by PeptideProphet (64) and ProteinProphet (65) in the Trans-
Proteomic Pipeline (TPP, v. 3.3.0) (http://tools.proteomecenter.org/software.php). Only 
proteins with probability ≥ 0.9000 and peptides with probability ≥ 0.8000 were used for 
quantitation.
Lipidomics and multiple reaction monitoring profiling
Lipid extraction from kidney tissue was performed according to the Bligh & Dyer protocol 
(66). The multiple reaction monitoring (MRM) profiling approach was applied to investigate 
the lipid profile of oxidized phospholipids. MRM uses direct sample injection and functional 
group profiling by using class-specific product ion (67). For the analysis of phospholipids 
(PL), the Lipid Maps database was used to pull the parent ions and the specific lipid class-
related product ion was added to obtain a list of transitions to be monitored by MRM scan. 
For the oxidized PL profile methods, we added the expected m/z value shift for one or two 
oxidation events to the parent mass of each lipid.
The lipid extracts were diluted in ACN+MeOH+300mM NH4Ac 3:6.65:0.35 (v/v). Mass 
spectrometry was performed as described in detail in de Lima et al (67). Briefly, for the MS 
analysis we used a capillary pump (G1376A, Agilent Technologies), operated with a flow of 
20μL/min and a pressure of 200 bar, connected to a autosampler (1100 series, Agilent 
Technologies) to deliver 8μL of sample to the ESI source of an Agilent 6410 QQQ mass 
spectrometer (Agilent Technologies), operated at the source with capillary voltage of 3.5–5 
kVand gas flow of 5.1 L/min at 300°C. Xcalibur data files (Agilent Technologies) were 
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processed using an in-house script and lists containing MRM transitions and the respective 
ion intensity values were exported to Microsoft Excel. Absolute ion intensity of all 
monitored transitions were compared to blank samples. Transitions that yielded a signal 
above the value seen in blank samples were used for comparative analysis. Subsequent 
statistical analyses were performed using MetaboAnalyst software (68). Samples were 
normalized by kidney weight. The Fisher’s exact test was used to compare the relative fold 
changes of statistically different lipids by grouping increased or decreased fold changes 
together as a categorical variable.
Oxidative DNA Damage Assay
Oxidative DNA damage was measured using an ELISA kit against 8-hydroxy-2’-
deoxyguanosine (8OHdG) from Enzo Life Sciences (Cat #ADI-EKS-350) according to the 
manufacturer protocol. Samples from the lung and kidney were lysed in RIPA lysis and 
extraction buffer (ThermoFisher Scientific, Cat. #89900) supplemented with Halt Protease 
and Phospatase single use inhibitor cocktail (ThermoFisher Scientific, Cat. #78442) in the 
Precellys tissue homogenizer (Bertin). Total protein concentration was measured using a 
modified Lowry assay from Bio-Rad (Cat. #5000111). The concentration of 8OHdG in 
tissue lysates was normalized to total protein concentration. Oxidative DNA damage for the 
serum samples from IRI-injured mice was measured using an ELISA kit against 8-
hydroxy-2’-deoxyguanosine (8OHdG) from Cell Biolabs (Cat. #STA-320) according to the 
manufacturer’s protocol.
Measurement of Tamm Horsfall Protein (THP)
THP concentrations in human plasma samples were measured using an ELISA kit from 
Sigma Aldrich (Cat. #RAB0751) according to the manufacturer protocol.
Clinical Studies
During a 24-month period, from June 2013 through June 2015, all planned liver transplant 
recipients (LT) at University of Sao Paulo, Brazil, were screened prior to surgery for 
enrollment. Exclusion criteria were: age less than 18 years, need for dialysis preoperatively, 
combined liver and kidney transplant, chronic kidney disease stage 5, and previous kidney or 
liver transplant. One hundred eligible patients were enrolled after voluntary informed 
consent was obtained as per the guidelines of the Institution Ethics Committee. The 
University of Sao Paulo Ethics Committee approved the study under the protocol 
number:CAAE:06636513.4.0000.0068., following the Principles of the Declaration of 
Istanbul and the Declaration of Helsinki. Conforming to national guidelines, the protocol is 
registered in https://clinicaltrials.gov by the identifier NCT 02095431.
Of this cohort, we selected 41 patients, 7 with no AKI and 34 patients who developed at 
least stage 1 AKI, to include in our analysis. Baseline characteristics of these 34 patients 
were compared to 9 control subjects enrolled in a study evaluating Normal Ranges of 
Biomarkers of Kidney Injury in a Healthy Population. The control cohort included subjects 
between the ages of 18–90 with no known medical conditions enrolled following informed 
consent.
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Baseline kidney function and pertinent clinical variables were extracted from electronic 
medical records (EMR). Blood samples were collected simultaneously in the perioperative 
period of LT, before induction of anesthesia and at various points after surgery. Vital signs, 
process of care and lab results were recorded daily for 7 days after LT. We recorded past 
medical history and baseline information and collected blood (~10mL), and urine (~250mL) 
samples. Samples from these cohorts were stored at −70 °C in the O’Brien Center Core A 
Laboratory at University of California San Diego.
Outcomes including the development of AKI, severity stage using the KDIGO criteria (28), 
need for dialysis and mortality were assessed in the intensive care unit (ICU), at hospital 
discharge, and 60 days after enrollment.
HEK293-TRPM2 Calcium Influx Assay
TRPM2-HEK293 recombinant cell line was purchased from BPS Bioscience (Cat. # 90331). 
The cells were propagated in culture according to the manufacturer’s instructions, and 
TRPM2 channel expression was induced with 0.2 μg/ml Doxycycline (Fisher Scientific, Cat. 
# ICN 19504401) 24 hours prior to Ca2+ influx experiment. Ca2+ influx was measured in a 
96-well format in triplicates, using reagents provided in the Fluo-4 NW Calcium Assay Kit 
(Molecular Probes, Cat. # F36206). Cells in Ca2+-free assay buffer, were loaded with the 
reporter dye Fluo-4 and stimulated with 1.7 mM H2O2. The fluorescence was monitored for 
~10 min, prior to addition of 10 mM CaCl2, and the readings continued for another 10 min, 
at which point the plateau was reached. In the inhibition experiments, TRP channel blocker 
ACA was used at 10 μM, while THP was used at 1 μg/ml, unless otherwise indicated. Cells 
were incubated with the THP or ACA in assay buffer for 20 min prior to stimulation with 
H2O2. In addition to the triplicate format, most experiments were repeated a minimum of 
two additional times with consistent results.
Bioinformatic analysis
Bioinformatic analysis of differentially expressed proteins was performed using Ingenuity 
Pathway Analysis (IPA, Quiagen). Gene E (Broad Institute: https://
software.broadinstitute.org/GENE-E/) and MetaboAnalyst 4.0 (68) were also used to 
perform statistical clustering and generate heat maps.
Statistical Analysis
Values of each experimental group are reported as mean ± standard deviation unless 
otherwise indicated. All statistical tests were performed using GraphPad Prism software 
unless otherwise noted. A two tailed t-test was used to examine the difference in means for 
continuous data. A paired t-test was used for samples from the same patient collected at 
different times. The Fisher’s exact test was used to determine differences between 
categorical variables. Simple linear regressions were used to determine relationships 
between two continuous variables. Statistical significance was determined at p< 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. THP inhibits activation of the RAC1/p-JNK signaling pathway
(A) Transcriptomic analysis of laser micro-dissected S3 proximal tubules from THP−/− and 
THP+/+ mouse kidney.
(B) Canonical pathway analysis (Ingenuity) of differentially expressed transcripts and 
pathways with Z score >1.5 or <−1.5 are shown with their predicated activation state in the 
S3 tubules of THP−/− mice.(C) Triplicate groups of HK-2 cells were treated with THP 
(1μg/ml) or vehicle for 6 hours. Protein extraction was followed by quantitative label-free 
proteomics. Differentially expressed proteins were identified (shown in heat map).
(D) Canonical pathway analysis of the proteomic data from C was performed and pathways 
with Z score >2 or <−2 are shown with their predicated activation state in the THP-
stimulated HK-2 cells.RAC1
(E) In the left panel, immunofluorescence confocal microscopy shows shifting of RAC1 
(red) in THP−/− mice to the basolateral domain of S3 segments (right) compared to a 
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cytoplasmic localization in THP+/+ (left). Insets show a higher magnification of the areas 
indicated by arrowheads (Arrow points to basolateral RAC1). RAC1 shift is a surrogate for 
its activation. In the right panel, THP−/− mouse kidneys (n=5 per group) are shown.
(F) Left panel: active RAC1 was immunoprecipated from total kidney lysates of THP+/+ and 
THP−/− kidneys (n=5–6 per group, sample “a” of the THP−/− group bridges the two 
immunoblots).Right panel: quantification of the immunoprecipitation experiment.
(G) Phosphorylated JNK was assayed from nuclear extracts of total kidney lysates by 
immunoblot (left) and quantitated (right) by band densitometry.
(H) Immunoblot of H2O2-dependent JNK activation following treatment with 1 μg/mL of 
THP in the left panel, quantitated in the right panel.
Scatter plots are mean ± standard deviation. * denotes statistical significance (p<0.05), ** 
denotes statistical significance (p<0.01), *** denotes statistical significance (p<0.001). MW 
= molecular weight, kDa = kiloDaltons.
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Fig. 2. THP inhibits activation of p-C-JUN
(A-C) Sections from the outer medulla of kidneys from THP+/+ and THP−/− mice were 
stained for phosphorylated (active) c-JUN (p-C-JUN, A). Volumetric tissue exploration and 
analysis (VTEA) was used to quantify the percentage of cells positive for p-c-JUN staining 
(B). In C, 3D rendering of a representative p-c-JUN stained image is overlaid with the 
VTEA gating.
Scatter plot error bars represent mean ± standard deviation, * denotes (p< 0.05), ** denotes 
(p<0.01). M-OS = Medulla, outer stripe. CX = Cortex.
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Fig. 3. THP−/− mice have increased oxidative stress and damage within the kidneys and 
systemically
(A) Live imaging with the ROS-sensitive dye H2DCFDA in kidneys of THP+/+ and THP−/− 
mice (inset: background fluorescence) in the left panel is quantitated in the right panel (n=3–
4 per group)
(B) H2O2 concentrations in kidney lysates from THP+/+ and THP−/− mice (n=5 per group). 
Values were normalized to the amount of protein present in each lysate.
(C) Heat map of oxidized phosphatidylcholine (PC) and phosphatidylethanolamine (PE) 
concentrations in the kidneys of THP+/+ and THP−/− mice (n=3 per group).
(D-F) Concentration of 8OHdG, a marker of oxidative DNA damage, in the kidney (D, n = 
7–15 per group), serum (E, n = 15–17 per group) and lungs (F, n = 8 per group) of THP−/− 
mice compared to THP+/+ mice. Scatter plots errors bars represent mean ± standard 
deviation.
* denotes statistical significance between the two groups (p< 0.05). *** denotes statistical 
significance between the two groups (p< 0.001).
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Fig. 4. Serum THP decreases and oxidative DNA damage increases following ischemic AKI in 
THP+/+ mice
(A) Serum THP concentrations of THP+/+ mice before and 24 hours following IRI surgery 
(n=15 mice)
(B) Serum DNA damage concentrations of THP+/+ mice before and 24 hours following IRI 
surgery (n=15 mice)
(C) Serum concentrations of kidney injury markers Cystatin C, NGAL and Osteopontin in 
THP+/+ mice before and 24 hours following IRI surgery (n=15 mice)
Scatter plots are mean ± standard deviation. ** denotes statistical significance (p<0.01). *** 
denotes statistical significance (p<0.001). **** denotes statistical significance (p<0.0001).
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Fig. 5. Plasma THP decreases and oxidative DNA damage increases in AKI patients following 
transplant surgery
(A) Correlation of THP and 8OHdG concentrations from all time-points for AKI cohort and 
control participants (n=43)
(B) Pre-surgery plasma THP concentrations compared to 18 hours post-surgery 
concentrations (paired analysis, n=34)
(C) Pre-surgery plasma 8OHdG concentrations compared to 18 hours post-surgery 
concentrations (paired analysis, n=34)
(D) Correlation of pre-surgery plasma concentrations of THP with plasma 8OHdG levels 
collected 18 hours post-surgery (n=34, R2 = 0.23, p < 0.05)
Scatter plot error bars are mean ± standard deviation. * denotes statistical significance 
(p<0.05). **** denotes statistical significance (p<0.0001).
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Fig. 6. Oxidative DNA damage is associated with mortality and need for dialysis in AKI patients 
following transplant surgery
(A-B) Pre-surgery (A) and post-surgery (B) plasma concentrations of 8OHdG in patients 
who did or did not survive following transplant surgery and development of AKI. (n=34)
(C-D) Pre-surgery (C) and post-surgery (D) plasma concentrations of THP in patients who 
did or did not survive following transplant surgery and development of AKI. (n=34)
(E-F) Pre-surgery (E) and post-surgery (F) plasma concentrations of 8OHdG in patients who 
did or did not receive dialysis following transplant surgery and development of AKI. (n=34)
** denotes statistical significance between the two groups (p< 0.01).
*** denotes statistical significance between the two groups (p< 0.001).
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Fig. 7. THP inhibits TRPM2 calcium influx in vitro and TRPM2 inhibition in vivo reduces 
oxidative damage
(A-D) HEK293 cells expressing a tetracycline-inducible TRPM2 channel were treated with 
doxycycline or vehicle control (vehicle control, no TRPM2) for 24 hours before loading 
with the calcium indicator Fluo-4. Cells were pre-treated with THP, human serum albumin 
(HSA) or N-(p-amylcinnamoyl) anthranilic acid (ACA), respectively, prior to activation of 
the TRPM2 channel with H2O2. Calcium influx was measured following addition of 
extracellular calcium (CaCl2). In (A) pre-treatment with 1 μg/ml THP is shown. In (B) pre-
treatment with 1 μg/ml THP is compared to 1 μg/ml HSA. In (C), pre-treatment with 0.01 
μg/ml, 0.1 μg/ml and 1 μg/ml THP are compared. In (D), treatment with 1 μg/ml THP is 
compared to 25 μM ACA, a small molecule inhibitor of TRPM2. Representative results are 
shown from a single experiment (n=3 wells per treatment condition).
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(E) Concentration of oxidative DNA damage (8OHdG) in THP−/− mice treated with the 
TRPM2 inhibitor 2-aminoethyoxydiphenyl borate (2-APB, 16 mg/kg) or vehicle (10% 
DMSO/90% sterile saline) for three days (n=7–8 mice/group).
(F) Concentration of oxidative DNA damage (8OHdG) in THP−/− and THP+/+ mice treated 
with TRPM2 inhibitor 2-APB (16 mg/kg) or vehicle (10% DMSO/90% sterile saline) for 
three days before performing a 22-minute bilateral clamping of the renal artery followed by 
six hour recovery. (n=7–8 mice/group).
Scatter plots are mean ± standard deviation. * denotes statistical significance (p<0.05). **** 
denotes statistical significance (p<0.0001)
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Fig. 8. Inhibition of TRPM2 blocks JNK activation in HK-2 cells
(A) Immunoblot for TRPM2 in HK-2 cell lysate.
(B) Immunoblot of H2O2-dependent JNK activation following treatment with 25 μM ACA in 
the left panel, quantitated in the right panel.
Scatter plots are mean ± standard deviation. * denotes statistical significance (p<0.05) *** 
denotes statistical significance (p<0.001). **** denotes statistical significance (p<0.0001). 
kDa = kiloDaltons.
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Table 1.
Characteristics of the AKI cohort
Demographic and clinical data for a cohort of liver transplant recipients who developed acute kidney injury 
following transplant surgery.
Sex 56%
 Male 44%
 Female
Age (years) 53.5 ± 11.3
Race
 Caucasian 85%
 African 3%
 Hispanic 9%
 Asian 3%
Body Mass Index (kg/m2) 27.5 ± 5.03
Pre-surgery Plasma 8OHdG (ng/mL) 11.8 ± 8.14
Post-surgery Plasma 8OHdG (ng/mL) 16.3 ± 11.8
Pre-surgery Plasma THP (ng/mL) 291 ± 258
Post-surgery Plasma THP (ng/mL) 102 ± 93.6
Pre-Surgery eGFR (mL/min/1.73 m2) 67.8 ± 33.0
Pre-surgery Plasma Creatinine (mg/dL) 1.32 ± 0.807
Post-surgery Plasma Creatinine (mg/dL) 1.53 ± 0.689
Acute Kidney Injury Stage
 Stage 1 15%
 Stage 2 29%
 Stage 3 56%
Received Dialysis 47%
60 Day Survival 77%
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